CPC A61K 35/28 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0048 (2013.01); A61K 31/5575 (2013.01); A61P 27/10 (2018.01); C12N 5/0663 (2013.01); C12N 15/113 (2013.01); A61K 45/06 (2013.01); C12N 2310/14 (2013.01); C12N 2310/141 (2013.01); C12N 2320/30 (2013.01)] | 15 Claims |
1. A method of treating a subject with glaucoma, comprising:
selecting a subject with glaucoma, and
locally administering to an eye of the subject a therapeutically effective amount of an adenoviral associated virus (AAV) vector comprises at least three of a nucleic acid molecule encoding hsa-miR-17, a nucleic acid molecule encoding hsa-miR-26a-1, a nucleic acid molecule encoding hsa-miR-30c-2, a nucleic acid molecule encoding hsa-miR-92a-1, a nucleic acid molecule encoding rno-miR-292, and a nucleic acid molecule encoding hsa-miR-182,
thereby treating the glaucoma in the subject.
|